Patents by Inventor Christiane Ferran

Christiane Ferran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL THERAPY TO ACHIEVE GLYCEMIC CONTROL
    Publication number: 20210283223
    Abstract: The disclosure relates to the use of A20 to restore glycemic control in a subject in need thereof, for example, a subject having diabetes. This novel approach provides non-insulin based therapy for diabetes.
    Type: Application
    Filed: August 15, 2017
    Publication date: September 16, 2021
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Christiane Ferran, Cleide Da Silva, Alessandra Mele
  • Use of pro-apoptotic factors in treatment of atherosclerosis
    Patent number: 7297685
    Abstract: The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: November 20, 2007
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Christiane Ferran, Maria B. Arvelo
  • Measurement of protective genes in allograft rejection
    Patent number: 6900015
    Abstract: The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: May 31, 2005
    Assignees: Beth Israel Deaconess Medical Center, Inc., Cornell Research Foundation, Inc.
    Inventors: Yingyos Avihingsanon, Nali Ma, Terry B. Strom, Miguel C. Soares, Christiane Ferran, Manikkam Suthanthiran
  • Use of pro-apoptotic factors in treatment of atherosclerosis
    Publication number: 20030207838
    Abstract: The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 6, 2003
    Inventors: Christiane Ferran, Maria B. Arvelo
  • Measurement of protective genes in allograft rejection
    Publication number: 20020132235
    Abstract: The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.
    Type: Application
    Filed: February 6, 2001
    Publication date: September 19, 2002
    Inventors: Yingyos Avihingsanon, Nalli Ma, Terry B. Strom, Miguel C. Soares, Christiane Ferran, Manikkam Suthanthiran
  • Use of pro-apoptotic factors in treatment of atherosclerosis
    Publication number: 20010053769
    Abstract: The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.
    Type: Application
    Filed: January 19, 2001
    Publication date: December 20, 2001
    Inventors: Christiane Ferran, Maria B. Arvelo